Urinary tract symptoms in postmenopausal women Lower urinary tract symptoms Administration, Intravaginal Estriol
Conditions
Interventions
Estriol 0.03 mg plus Lactobacillus acidophilius vaginal tablet,Placebo composed of microcrystalline cellulose, magnesium stearate and silicon dioxide
Experimental Drug,Placebo Comparator Drug
vaginal estriol plus lactobacilli,Placebo
Sponsors
Khon Kaen University
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: Postmenopausal women with urinary tract symptoms (frequency or urgency or dysuria or nocturia or stress urinary incontinence or urgency urinary incontinence)
Exclusion criteria
Exclusion criteria: Previous vaginal or urethral surgery or hysterectomy, Pelvic organs prolapsed stage 3-4, History of endometrial hyperplasia or cancer, History of breast cancer, Undiagnosed AUB, Allergic reaction to vaginal tablet, History of vaginal estrogen or systemic estrogen use in previous month, History of muscarinic antagonist or beta-3 adrenergic agonist in previous month, Currently using the vaginal pessary, BMI exceeding 25 kg/m*m, Cannot understand Thai language, Deny participation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Improvement of urinary tract symptoms at the end of the study visual analog scale | — |
Secondary
| Measure | Time frame |
|---|---|
| Mean symptoms score at the end of the study Visual analog scale,Quality of life at the end of the study IIQ-7,Satisfaction at the end of the study Visual analog scale,Adverse effect at the end of the study Questionnaire | — |
Countries
Thailand
Contacts
Public ContactApiwat Jongjakapun
Khon Kaen University
Outcome results
None listed